95d76fd3-540d-4c50-9ea9-b50fe2c37639
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 59.5318275154004
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- HEDGEHOG_SIGNALING+0.460
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.450
- TNFA_SIGNALING_VIA_NFKB+0.440
- ANGIOGENESIS+0.410
- UV_RESPONSE_DN+0.390
- KRAS_SIGNALING_UP+0.240
- MYOGENESIS+0.230
- INFLAMMATORY_RESPONSE+0.210
- IL2_STAT5_SIGNALING+0.170
- WNT_BETA_CATENIN_SIGNALING+0.170
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.640
- MYC_TARGETS_V1-0.550
- E2F_TARGETS-0.530
- MTORC1_SIGNALING-0.520
- FATTY_ACID_METABOLISM-0.510
- CHOLESTEROL_HOMEOSTASIS-0.430
- G2M_CHECKPOINT-0.420
- ADIPOGENESIS-0.410
- DNA_REPAIR-0.410
- GLYCOLYSIS-0.410
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 3383d8e1-d61d-4346-a589-007ad2829e36 | — | — | 0.908 |
| 2 | SRR11296799 | — | — | 0.906 |
| 3 | 7900174d-af00-444f-a5b2-226a45f7e76a | — | — | 0.906 |
| 4 | ebff0d05-b930-42b7-a428-694cef63ebb5 | — | — | 0.897 |
| 5 | 66e5440a-6b08-43cc-b007-82ac3f5221d1 | — | — | 0.888 |
| 6 | TCGA-56-8628-01A-11R-2403-07 | — | cohortSQ1 | 0.885 |
| 7 | SRR975557 | — | — | 0.882 |
| 8 | MBCProject_3896_T1_RNA | — | A | 0.882 |
| 9 | SRR9879291 | — | cohortMD2 | 0.874 |
| 10 | TCGA-A2-A4RY-01A-31R-A266-07 | — | A | 0.871 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 19 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| HEDGEHOG_SIGNALING | 0.460 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.450 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.440 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.410 | Remibrutinib | — uncovered |
| UV_RESPONSE_DN | 0.390 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.240 | Inavolisib | — uncovered |
| MYOGENESIS | 0.230 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.210 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.170 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.170 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.160 | Remibrutinib | — uncovered |
| COAGULATION | 0.140 | Binimetinib | — uncovered |
| TGF_BETA_SIGNALING | 0.130 | Inavolisib | — uncovered |
| HYPOXIA | 0.120 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.080 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.060 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.040 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.030 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.010 | Idelalisib | — uncovered |